Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
Akero Therapeutics, Inc.

Akero Therapeutics, Inc. (AKRO) Stock Overview

Explore Akero Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.

AKRO●NASDAQ
HealthcareBiotechnology
$54.65
$0.00(0.00%)
U.S. Market is Open · 15:10

Akero Therapeutics, Inc. (AKRO)

Meyka AI Score

Z

Key Financials

Market Cap4.5B
P/E Ratio-19.87
EPS (TTM)$-3.75
ROE-0.22%
Fundamental Analysis

AI Price Forecasts

1 MonthN/A
3 MonthsN/A
1 Year Target$46.08

AKRO Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Akero Therapeutics, Inc. (NASDAQ: AKRO) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Akero Therapeutics, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of AKRO on the NASDAQ shows an RSI of N/A, suggesting the stock is in a an undetermined condition. Our forecasting models predict a 12-month price target of $46.08 for the NASDAQ listing.

Key metrics behind Akero Therapeutics, Inc.'s NASDAQ-traded stock include a P/E ratio of -19.87 and a market capitalization of 4.5B. Combined with our AI analysis, these give both institutional and retail investors a clear view of AKRO on the NASDAQ.

Price Performance (NASDAQ: AKRO)

1-Day Change
N/A
5-Day Change
N/A
1-Month Change
N/A
3-Month Change
17.55%
6-Month Change
8.50%
Year-to-Date (YTD) Change
N/A
1-Year Change
108.91%
3-Year Change
23.95%
5-Year Change
89.17%
All-Time (Max) Change
198.31%

Contact Information

https://www.akerotx.com
650 487 6488
601 Gateway Boulevard, South San Francisco, CA, 94080

Company Facts

690 Employees
IPO DateJun 20, 2019
CountryUS

Frequently Asked Questions